Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study

Bertus Eksteen, Christopher L Bowlus, Aldo J Montano-Loza, Eric Lefebvre, Laurent Fischer, Pamela Vig, Eduardo Bruno Martins, Jawad Ahmad, Kidist K Yimam, Paul J Pockros, Jordan J Feld, Gerald Minuk, Cynthia Levy, Bertus Eksteen, Christopher L Bowlus, Aldo J Montano-Loza, Eric Lefebvre, Laurent Fischer, Pamela Vig, Eduardo Bruno Martins, Jawad Ahmad, Kidist K Yimam, Paul J Pockros, Jordan J Feld, Gerald Minuk, Cynthia Levy

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease with no approved treatments. C-C chemokine receptor types 2 and 5 (CCR2/CCR5) play an important role in inflammation and fibrosis and are potential therapeutic targets for PSC. We evaluated the efficacy and safety of cenicriviroc (CVC), a dual antagonist of CCR2 and CCR5, for the treatment of PSC. This was a single-arm, open-label, exploratory study of CVC in adults with a clinical diagnosis of PSC, serum alkaline phosphatase (ALP) ≥1.5 times the upper limit of normal (ULN), with or without inflammatory bowel disease, across eight sites in the United States and Canada. The primary endpoint was percent change in ALP over 24 weeks; key secondary efficacy endpoints were proportion of participants who achieved ALP normalization and overall response (decrease to <1.5 times the ULN or 50% decrease). Of the 24 participants, 20 completed the study. The mean age was 43 years, 50% were female, and the mean body mass index was 25 kg/m2. From a median ALP baseline of 369 U/L (range: 173, 1,377 U/L), a median absolute reduction of 49.5 U/L (range: -460, 416 U/L) was achieved at week 24, corresponding to a median reduction of 18.0% (range: -46%, 89%). No participant achieved ALP normalization or a 50% decrease; 2 participants (10%) achieved a reduction in ALP to < 1.5 times the ULN, and 4 had ≥25% increase. Twenty participants (83.3%) reported at least one adverse event; most were mild to moderate in severity. The most frequent events were rash, fatigue, and dizziness. Conclusion: After 24 weeks of CVC treatment, adults with PSC achieved a modest reduction (median 18%) in the surrogate endpoint of ALP. CVC was well tolerated, and no new safety signals were observed. ClinicalTrials.gov identifier: NCT02653625.

© 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.

Figures

Fig. 1
Fig. 1
Percentage change in ALP levels from baseline in each individual participant over 24 weeks. Data are based on the intent‐to‐treat population analysis set and were evaluated at the screening visit (week −6), baseline (day 1), weeks 4, 8, 12, 16, and 24, and at the safety follow‐up visit (week 28). Abbreviation: Bsl, baseline.
Fig. 2
Fig. 2
Summary of change from baseline to week 24 in serum ALP by UDCA status (A) and IBD status (B) at screening. Results are displayed as median (minimum, maximum).

References

    1. Maggs JR, Chapman RW. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol 2008;24:377‐383.
    1. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364‐1369.
    1. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al. Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045‐2055.
    1. Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta‐analysis. Hepatology 2011;53:1590‐1599.
    1. Kaplan GG, Laupland KB, Butzner D, Urbanski SJ, Lee SS. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population‐based analysis. Am J Gastroenterol 2007;102:1042‐1049.
    1. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660‐678.
    1. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013;145:521‐536.
    1. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson Å, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321‐327.
    1. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet 2013;382:1587‐1599.
    1. Fiorotto R, Scirpo R, Trauner M, Fabris L, Hoque R, Spirli C, et al. Loss of CFTR affects biliary epithelium innate immunity and causes TLR4‐NF‐κB‐mediated inflammatory response in mice. Gastroenterology 2011;141:1498‐1508.e5.
    1. Spirlì C, Nathanson MH, Fiorotto R, Duner E, Denson LA, Sanz JM, et al. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. Gastroenterology 2001;121:156‐169.
    1. Lindström L, Hultcrantz R, Boberg KM, Friis‐Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013;11:841‐846.
    1. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High‐dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808‐814.
    1. Harada K, Nakanuma Y. Innate immunity in the pathogenesis of cholangiopathy: a recent update. Inflamm Allergy Drug Targets 2012;11:478‐483.
    1. Marra F, DeFranco R, Grappone C, Parola M, Milani S, Leonarduzzi G, et al. Expression of monocyte chemotactic protein‐1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Investig Med 1999;47:66‐75.
    1. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 2012;302:G1310‐G1321.
    1. Tabibian JH, O'Hara SP, Splinter PL, Trussoni CE, LaRusso NF. Cholangiocyte senescence by way of N‐ras activation is a characteristic of primary sclerosing cholangitis. Hepatology 2014;59:2263‐2275.
    1. Nakken KE, Nygård S, Haaland T, Berge KE, Arnkværn K, Ødegaard A, et al. Multiple inflammatory‐, tissue remodelling‐ and fibrosis genes are differentially transcribed in the livers of Abcb4 (‐/‐) mice harbouring chronic cholangitis. Scand J Gastroenterol 2007;42:1245‐1255.
    1. Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One 2016;11:e0158156.
    1. Mossanen JC, Krenkel O, Ergen C, Govaere O, Liepelt A, Puengel T, et al. Chemokine (C‐C motif) receptor 2‐positive monocytes aggravate the early phase of acetaminophen‐induced acute liver injury. Hepatology 2016;64:1667‐1682.
    1. Puengel T, Krenkel O, Kohlhepp M, Lefebvre E, Luedde T, Trautwein C, et al. Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury. PLoS One 2017;12:e0184694.
    1. Yu D, Cai SY, Mennone A, Vig P, Boyer JL. Cenicriviroc, a cytokine receptor antagonist, potentiates all‐trans retinoic acid in reducing liver injury in cholestatic rodents. Liver Int 2018;38:1128‐1138.
    1. Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology 2018;67:1270‐1283.
    1. Guicciardi ME, Trussoni CE, Krishnan A, Bronk SF, Lorenzo Pisarello MJ, O'Hara SP, et al. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 2018;69:676‐686.
    1. Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, et al. A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 2018;67:1754‐1767.
    1. Saiman Y, Friedman SL. The role of chemokines in acute liver injury. Front Physiol 2012;3:213.
    1. Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 2011;10:509‐536.
    1. Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009;50:185‐197.
    1. Ponsioen CY, Chapman RW, Chazouillères O, Hirschfield GM, Karlsen TH, Lohse AW, et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process. Hepatology 2016;63:1357‐1367.
    1. Ponsioen CY, Lindor KD, Mehta R, Dimick‐Santos L. Design and endpoints for clinical trials in primary sclerosing cholangitis. Hepatology 2018;68:1174‐1188.
    1. Boonstra K, de Vries EM, van Geloven N, van Erpecum KJ, Spanier M, Poen AC, et al. Risk factors for primary sclerosing cholangitis. Liver Int 2016;36:84‐91.
    1. Balasubramaniam K, Wiesner RH, LaRusso NF. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. Gastroenterology 1988;95:1395‐1398.
    1. Olsson R, Broomé U, Danielsson Å, Hägerstrand I, Järnerot G, Lööf L, et al. Spontaneous course of symptoms in primary sclerosing cholangitis: relationships with biochemical and histological features. Hepatogastroenterology 1999;46:136‐141.
    1. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High‐dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5‐year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464‐1472.
    1. Stanich PP, Björnsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis 2011;43:309‐313.
    1. Platt AM, Bain CC, Bordon Y, Sester DP, Mowat AM. An independent subset of TLR expressing CCR2‐dependent macrophages promotes colonic inflammation. J Immunol 2010;184:6843‐6854.
    1. Ye X, Liu S, Hu M, Song Y, Huang H, Zhong Y. CCR5 expression in inflammatory bowel disease and its correlation with inflammatory cells and β‐arrestin2 expression. Scand J Gastroenterol 2017;52:551‐557.
    1. Kowdley KV, Bowlus CL, Levy C, Vuppalanchi R, Floreani A, Andreone P, et al. The AESOP trial: a randomized, double‐blind, placebo‐controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis. Hepatology 2017;66:1254A. Abstract number: LB‐2.
    1. Thompson M, Saag M, DeJesus E, Gathe J, Lalezari J, Landay AL, et al. A 48‐week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment‐naive HIV‐infected adults with C‐C chemokine receptor type 5‐tropic virus. AIDS 2016;30:869‐878.
    1. de Vries EMG, Färkkilä M, Milkiewicz P, Hov JR, Eksteen B, Thorburn D, et al. Enhanced liver fibrosis test predicts transplant‐free survival in primary sclerosing cholangitis, a multi‐centre study. Liver Int 2017;37:1554‐1561.
    1. Vesterhus M, Holm A, Hov JR, Nygård S, Schrumpf E, Melum E, et al. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. J Hepatol 2017;66:1214‐1222.
    1. Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygård S, Godang K, et al. Enhanced liver fibrosis score predicts transplant‐free survival in primary sclerosing cholangitis. Hepatology 2015;62:188‐197.
    1. Nielsen MJ, Veidal SS, Karsdal MA, Orsnes‐Leeming DJ, Vainer B, Gardner SD, et al. Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int 2015;35:429‐437.
    1. Leeming DJ, Birot S, Goodman Z, McKibben A, Seyedkazemi S, Muthian S, et al. Percent change in plasma collagen type III formation (PRO‐C3) is related to change in liver fibrosis stage: CENTAUR study. Poster P2324 presented at the American Association for the Study of Liver Diseases: The Liver Meeting; November 9‐13, 2018; San Francisco, CA.
    1. Trauner M, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, Landis CS, et al. The nonsteroidal farnesoid X receptor agonist GS‐9674 improves liver biochemistry and decreases serum bile acids in patients with primary sclerosing cholangitis: a phase 2, randomized, placebo‐controlled trial. Oral presentation 43 presented at the American Association for the Study of Liver Diseases: The Liver Meeting; November 9‐13, 2018; San Francisco, CA.
    1. Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017;67:549‐558.
    1. Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison S, Landis CS, et al. NGM282, an engineered analogue of FGF19, significantly improves markers of bile acid synthesis, hepatic injury and fibrosis in PSC patients: results of a phase 2, multicenter, randomized, double‐blind, placebo‐controlled trial. J Hepatol 2018;68:S101. Abstract number: LBO‐002.
    1. Ratziu V, Sanyal A, Francque S, Wong VW, Loomba R, Goodman Z, et al. Cenicriviroc treatment for adults with non‐alcoholic steatohepatitis: year 2 analysis of the phase 2b CENTAUR study. Oral presentation presented at the European Association for the Study of the Liver: The International Liver Congress; April 11‐15, 2018; Paris, France.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere